Longstanding Patent Row Over ‘Carve-Out’ Label Ends In Cert Denial
WASHINGTON, D.C. — A decision on rehearing by the Federal Circuit U.S. Court of Appeals that reinstated a $234 million award in favor of GlaxoSmithKline LLC (GSK) will stand in light...To view the full article, register now.
Already a subscriber? Click here to view full article